JAK2, Janus kinase 2, 3717

N. diseases: 644; N. variants: 54
Disease: Eczema ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0013595
Disease: Eczema
Eczema 		0.030 Biomarker disease BEFREE Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis. 31629805 2020
CUI: C0013595
Disease: Eczema
Eczema 		0.030 GeneticVariation disease BEFREE Rare coding variants associated with AD are further enriched in 5 genes (IL-4 receptor [IL4R], IL13, Janus kinase 1 [JAK1], JAK2, and tyrosine kinase 2 [TYK2]) of the IL13 pathway, all of which are targets for novel systemic AD therapeutics. 31707051 2019
CUI: C0013595
Disease: Eczema
Eczema 		0.030 Biomarker disease BEFREE Taken together, a key role of the JAK2/STAT3/Sin3a signaling pathway in thymic stromal lymphopoietin-mediated immune response in normal human epidermal keratinocytes might give us clues to understanding the pathological signal transductions in atopic dermatitis. 27498343 2016